Roughly half of postmenopausal women experience some degree of vaginal atrophy, yet only a minority receive treatment — a gap documented in surveys such as REVIVE, published in the Journal of Sexual Medicine. The condition — now more accurately called genitourinary syndrome of menopause (GSM) — causes dryness, burning, painful intercourse, and recurrent urinary symptoms that can persist for years without intervention. Unlike hot flashes, GSM rarely improves on its own, but several effective and reasonably safe treatments exist, and the right choice is one you make together with a clinician.
What Vaginal Atrophy Is and How Common It Is
Vaginal atrophy refers to thinning, drying, and inflammation of the vaginal walls due to declining estrogen. The term genitourinary syndrome of menopause was adopted in 2014 by the group now known as The Menopause Society (formerly the North American Menopause Society, or NAMS) together with the International Society for the Study of Women’s Sexual Health, because the condition affects the entire genitourinary tract — vulva, vagina, urethra, and bladder — not just the vagina.
According to The Menopause Society, prevalence estimates range widely — roughly 27 to 84 percent of postmenopausal women depending on the population studied — and symptoms tend to worsen rather than improve over time. Younger women on aromatase inhibitors for breast cancer, after surgical menopause, or with primary ovarian insufficiency can also develop GSM. For broader context on related conditions, see our medical conditions hub.
Causes and Contributing Factors
Estrogen maintains the elasticity, lubrication, and acidic pH of the vaginal environment. As estradiol declines after menopause, the vaginal epithelium thins, glycogen content drops, protective lactobacilli decrease, and pH rises from around 4.5 to greater than 5.0. This creates less elastic, drier, and more fragile tissue that is prone to friction injury and infection.
Beyond natural menopause, other contributors include surgical removal of the ovaries, pelvic radiation, chemotherapy, breast cancer endocrine therapy (especially aromatase inhibitors), postpartum and breastfeeding hypoestrogenism, smoking (which reduces estrogen and tissue perfusion), and certain medications. The American College of Obstetricians and Gynecologists notes that lack of regular sexual activity may also contribute to tissue changes over time.
Symptoms
Vaginal symptoms include dryness, burning, itching, soreness, and discharge that may be thin, watery, or slightly yellow. Sexual symptoms include decreased lubrication, painful intercourse (dyspareunia), post-coital bleeding from friction, and reduced arousal. Urinary symptoms include urgency, frequency, painful urination, and recurrent urinary tract infections — driven by changes to the urethra and trigone, which share an embryologic origin with the vagina.
Symptoms often develop gradually and may not be recognized as menopause-related. Many women endure them silently; surveys such as Women’s EMPOWER have found that fewer than half of women with GSM had ever discussed their symptoms with a healthcare provider. Because effective treatment exists, raising the subject — even briefly — is worthwhile.
How Vaginal Atrophy Is Diagnosed
Diagnosis is largely clinical. A clinician will take a focused history and perform a pelvic exam, which typically reveals pale, thin, less elastic vaginal mucosa, loss of rugae, and tissue that bleeds easily on contact. The introitus may be narrowed and the labia minora reduced.
Laboratory testing is generally unnecessary, though vaginal pH measurement (typically greater than 5.0 in GSM) can support the diagnosis. When discharge is present or symptoms are atypical, testing for infection — yeast, bacterial vaginosis, trichomoniasis — and consideration of dermatologic conditions such as lichen sclerosus is appropriate. Postmenopausal bleeding, even if light or attributed to atrophy, requires evaluation per ACOG guidance to rule out endometrial cancer.
Treatment Options
Treatment is individualized and decided with a clinician. For mild symptoms, non-hormonal options are often tried first. Long-acting vaginal moisturizers (used several times per week independent of intercourse) and personal lubricants (used during sexual activity) reduce friction and discomfort. Water-, silicone-, and hyaluronic acid-based products are widely available, and the Cleveland Clinic notes that hyaluronic acid moisturizers have some of the best evidence among non-hormonal options.
For moderate to severe GSM, low-dose vaginal estrogen is generally considered the most effective treatment, and it is prescriber-directed. Options include vaginal cream (estradiol or conjugated estrogens), low-dose vaginal tablets or inserts (such as Vagifem or Yuvafem), the estradiol vaginal ring (Estring), and a soft-gel insert (Imvexxy). Systemic absorption is minimal at recommended doses. The Menopause Society supports individualized use of low-dose vaginal estrogen — including in many women with a history of breast cancer, after discussion with their oncologist — and notes that endometrial protection with a progestogen is generally not required for standard low-dose vaginal estrogen. Your clinician will weigh your history and preferences when choosing a product and dose.
Other prescription options include intravaginal DHEA (prasterone, Intrarosa), which converts locally to estrogens and androgens, and oral ospemifene (Osphena), a selective estrogen receptor modulator approved for moderate to severe dyspareunia. Systemic hormone therapy also treats GSM but is not necessary if vaginal symptoms are the only concern; some women on systemic therapy still need additional vaginal estrogen for complete relief. All of these are prescription treatments that a clinician tailors to the individual — there is no one-size-fits-all regimen.
Energy-based devices such as fractional CO2 “vaginal laser” have been marketed for GSM, but the FDA issued a safety communication in 2018 cautioning against unapproved uses, and major societies do not recommend them as first-line therapy. Pelvic floor physical therapy can help with pain syndromes related to GSM and dyspareunia and is a reasonable adjunct for some women.
When to See a Doctor
Many women hesitate to bring up vaginal symptoms, but effective treatments are available and there is no need to suffer in silence. Schedule a visit if you have persistent dryness, burning, painful intercourse, or recurrent UTIs that began after menopause. Symptoms unresponsive to over-the-counter moisturizers and lubricants warrant a clinical evaluation, and any prescription therapy should be started under a clinician’s direction.
Always seek evaluation for postmenopausal bleeding regardless of how light it is or how easily it might be attributed to atrophy. New vulvar lesions, persistent itching unresponsive to treatment, or worsening pain despite therapy can indicate dermatologic conditions or, rarely, vulvar cancer.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience heavy vaginal bleeding causing dizziness or fainting, severe pelvic pain, a fever above 102 degrees with vaginal symptoms, or signs of severe infection.
Frequently Asked Questions
Is vaginal estrogen safe for breast cancer survivors?
The Menopause Society supports individualized use of low-dose vaginal estrogen in breast cancer survivors with bothersome GSM that has not responded to non-hormonal therapies, after discussion with their oncologist. Systemic absorption is minimal at recommended doses. Non-hormonal options such as vaginal moisturizers, and sometimes DHEA, may also be considered. This is a decision to make with your oncology and gynecology team, not on your own.
Do I need progesterone with vaginal estrogen?
Generally no. Standard low-dose vaginal estrogen products produce minimal systemic absorption and have not been shown to significantly increase endometrial thickness. ACOG and The Menopause Society do not recommend routine progestogen addition with low-dose vaginal estrogen, though any postmenopausal bleeding while on therapy should be evaluated by your clinician.
How long does it take vaginal estrogen to work?
Many women notice improvement within 2 to 4 weeks, with maximum benefit usually by about 12 weeks. Initial therapy is often daily for a couple of weeks followed by a maintenance schedule a few times per week. Treatment generally needs to continue long-term, because symptoms tend to return when therapy stops. Your prescriber will set the specific regimen.
Can vaginal atrophy cause UTIs?
Yes. Thinning of the urethra and changes in vaginal flora associated with GSM contribute to recurrent UTIs in postmenopausal women. Vaginal estrogen has been shown in randomized trials to reduce recurrent UTIs, often more effectively than long-term antibiotic prophylaxis — one reason to discuss it with your clinician if recurrent infections are a problem.
Living With GSM
Vaginal atrophy is one of the more treatable consequences of menopause, but it usually requires consistent, long-term therapy because the underlying tissue changes return when treatment stops. Starting with non-hormonal moisturizers and lubricants is reasonable for mild symptoms; women with moderate to severe GSM typically benefit from vaginal estrogen or another prescription option chosen with their clinician. Bringing up symptoms with your clinician — even briefly — opens the door to relief that can substantially improve sexual health, urinary comfort, and overall quality of life.
Quick summary: Vaginal atrophy, or genitourinary syndrome of menopause (GSM), is a common, treatable result of declining estrogen that causes dryness, painful intercourse, and urinary symptoms. Non-hormonal moisturizers and lubricants help mild cases; low-dose vaginal estrogen, vaginal DHEA (prasterone), and oral ospemifene are effective prescription options that a clinician selects and directs for you. Always have postmenopausal bleeding evaluated. This article is educational and is not a substitute for care from a qualified clinician.
Sources
- The Menopause Society (formerly NAMS) — genitourinary syndrome of menopause position statement and patient education (menopause.org)
- American College of Obstetricians and Gynecologists (ACOG) — vaginal dryness and menopause guidance
- Mayo Clinic — vaginal atrophy: symptoms and causes
- Cleveland Clinic — vaginal atrophy overview and treatment